|
|
Post by yash on Apr 1, 2020 5:19:06 GMT -5
|
|
|
|
Post by nxc2 on Apr 1, 2020 5:41:46 GMT -5
Note Patrick McCauley Chief Commercial Officer is not on executive mgmt team
|
|
|
|
Post by sportsrancho on Apr 1, 2020 6:06:40 GMT -5
Note Patrick McCauley Chief Commercial Officer is not on executive mgmt team
Thank you....Like was noted on here 3 weeks or so ago. |
|
|
|
Post by sportsrancho on Apr 1, 2020 6:23:58 GMT -5
So they want more shares so they can dilute and compensation at this share price!
And some of you guys wondered why we wanted change!!
|
|
|
|
Post by peppy on Apr 1, 2020 6:31:07 GMT -5
So they want more shares so they can dilute and compensation at this share price! And some of you guys wondered why we wanted change!! the change you want would've changed this? I never took a logic class in college. To approve an amendment to MannKind Corporation’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 280,000,000 shares to 400,000,000 shares (the “Authorized Shares Increase Proposal”); |
|
|
|
Post by sportsrancho on Apr 1, 2020 6:33:41 GMT -5
So they want more shares so they can dilute and compensation at this share price! And some of you guys wondered why we wanted change!! the change you want would've changed this? I never took a logic class in college. To approve an amendment to MannKind Corporation’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 280,000,000 shares to 400,000,000 shares (the “Authorized Shares Increase Proposal”); I think it absolutely would have, we’ve got a CEO that has ignored deals on the table, who insists on going alone without a partner. Opportunities overlooked by him and the Board of Directors. They are going to drive the stock into the gutter! |
|
|
|
Post by matt on Apr 1, 2020 6:56:49 GMT -5
Note Patrick McCauley Chief Commercial Officer is not on executive mgmt team
He is named as an officer under the section showing securities holdings, but not under the table of executive officers. Either he should be included on both lists or neither, but somebody missed this. These are the kind of minor errors that sneak through on the PRE14A, which is a preliminary filing, that often get corrected on the DEF14A. |
|
|
|
Post by rickf on Apr 1, 2020 7:01:47 GMT -5
So they want more shares so they can dilute and compensation at this share price! And some of you guys wondered why we wanted change!! I have been very reluctant but --- it is time! It seems that the only thing that is going down is - the ship - without the captain! He and the crew are grabbing all the bobbles they can before jumping ship! |
|
|
|
Post by morfu on Apr 1, 2020 7:02:03 GMT -5
the change you want would've changed this? I never took a logic class in college. To approve an amendment to MannKind Corporation’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 280,000,000 shares to 400,000,000 shares (the “Authorized Shares Increase Proposal”); I think it absolutely would have, we’ve got a CEO that has ignored deals on the table, who insists on going alone without a partner. Opportunities overlooked by him and the Board of Directors. They are going to drive the stock into the gutter! While I am also strictly against any avoidable dilution, you make little sense to me! The last partner was Sanofi and took in effect about 2/3 of the profit away from Mannkind, this 30% dilution would be a lesser evil. Your proposed change of how to sell Afrezza might benefit VDex (even so I think this is only a short term thing, their business model is doomed, they are not effective, patients can go to normal endos and educate themself), but it certainly is not in the interest of Mannkind with a solid trend in sales over 2 years, no one will be so foolish to change the concept at this point, you can stop it already!
There is no need to dilute right now, debt financing seems a much smarter choice if needed at all, I hope Jennifer Grancio and the other board members act in the interest of the shareholders and stop that nonsense! Last time we gave the management a package like that so they "would have options", they gave it away without need and wasted my money, do not give them option is the conclusion, they should just focus on getting Afrezza on the road, nothing else is needed at the moment, so they don´t need to dilute my shares.
Plus I still want to know we got that 20% Christmas dilution package in 2018, it still smells bad!
|
|
|
|
Post by sportsrancho on Apr 1, 2020 7:12:19 GMT -5
I think it absolutely would have, we’ve got a CEO that has ignored deals on the table, who insists on going alone without a partner. Opportunities overlooked by him and the Board of Directors. They are going to drive the stock into the gutter! While I am also strictly against any avoidable dilution, you make little sense to me! The last partner was Sanofi and took in effect about 2/3 of the profit away from Mannkind, this 30% dilution would be a lesser evil. Your proposed change of how to sell Afrezza might benefit VDex (even so I think this is only a short term thing, their business model is doomed, they are not effective, patients can go to normal endos and educate themself), but it certainly is not in the interest of Mannkind with a solid trend in sales over 2 years, no one will be so foolish to change the concept at this point, you can stop it already!
There is no need to dilute right now, debt financing seems a much smarter choice if needed at all, I hope Jennifer Grancio and the other board members act in the interest of the shareholders and stop that nonsense! Last time we gave the management a package like that so they "would have options", they gave it away without need and wasted my money, do not give them option is the conclusion, they should just focus on getting Afrezza on the road, nothing else is needed at the moment, so they don´t need to dilute my shares.
Plus I still want to know we got that 20% Christmas dilution package in 2018, it still smells bad!
I am not talking about Vdex, this has nothing to do with Vdex, this has to do with the Christmas massacre ..it looks like the same thing again when the share price is too low. It’s about the compensation. It’s about the possibility of another reverse split. And BTW you need to stop right now stalking my every post. |
|
|
|
Post by cretin11 on Apr 1, 2020 7:32:34 GMT -5
I think it absolutely would have, we’ve got a CEO that has ignored deals on the table, who insists on going alone without a partner. Opportunities overlooked by him and the Board of Directors. They are going to drive the stock into the gutter! While I am also strictly against any avoidable dilution, you make little sense to me! The last partner was Sanofi and took in effect about 2/3 of the profit away from Mannkind, this 30% dilution would be a lesser evil. Your proposed change of how to sell Afrezza might benefit VDex (even so I think this is only a short term thing, their business model is doomed, they are not effective, patients can go to normal endos and educate themself), but it certainly is not in the interest of Mannkind with a solid trend in sales over 2 years, no one will be so foolish to change the concept at this point, you can stop it already!
There is no need to dilute right now, debt financing seems a much smarter choice if needed at all, I hope Jennifer Grancio and the other board members act in the interest of the shareholders and stop that nonsense! Last time we gave the management a package like that so they "would have options", they gave it away without need and wasted my money, do not give them option is the conclusion, they should just focus on getting Afrezza on the road, nothing else is needed at the moment, so they don´t need to dilute my shares.
Plus I still want to know we got that 20% Christmas dilution package in 2018, it still smells bad!
i don’t agree with: “Mannkind with a solid trend in sales over 2 years, no one will be so foolish to change the concept at this point” |
|
|
|
Post by brotherm1 on Apr 1, 2020 7:38:11 GMT -5
Should this have not at least been preceded by some good news like the licensing or sale of a pipeline drug, or a partnership, or a milestone from RLS, a tranche from Midcap, or the a second molecule with UTHR, or at the very least, another $12.5M from UTHR? Oh well....looks like another reverse split. I know who I would like to see split.
|
|
|
|
Post by brotherm1 on Apr 1, 2020 7:41:39 GMT -5
This will certainly be followed up this morning before the opening bell with the at home fireside chat?
|
|
|
|
Post by otherottawaguy on Apr 1, 2020 7:45:05 GMT -5
MANNKIND CORPORATION 30930 Russell Ranch Road, Suite 300 Westlake Village, California 91362 (818) 661-5000 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held On Thursday, May 21, 2020 Dear Stockholder: You are cordially invited to attend the Annual Meeting of Stockholders of MannKind Corporation, a Delaware corporation (“MannKind”). Due to public health concerns arising from the COVID-19 pandemic, the meeting will be held live via the Internet on Thursday, May 21, 2020 at 10:00 a.m. U.S. Pacific Time. To attend, please visit www.virtualshareholdermeeting.com/MNKD2020. You will not be able to attend the Annual Meeting in person. The Annual Meeting will consider the following matters: 1. To elect the eight nominees named herein as directors to serve for the ensuing year and until their successors are elected; 2. To approve an amendment to MannKind Corporation’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 280,000,000 shares to 400,000,000 shares (the “Authorized Shares Increase Proposal”); 3. To approve an amendment to the MannKind Corporation 2018 Equity Incentive Plan to increase the number of shares authorized for issuance under the 2018 Equity Incentive Plan (the “2018 Plan”) by 12,500,000 shares; 4. To approve, on an advisory basis, the compensation of the named executive officers of MannKind, as disclosed in MannKind’s proxy statement for the Annual Meeting; 5. To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm of MannKind for its fiscal year ending December 31, 2020; and 6. To transact such other business as may properly come before the meeting or any adjournment or postponement thereof. These items of business are more fully described in the proxy statement accompanying this notice. The record date for the Annual Meeting is March 22, 2020. Only stockholders of record on that date may vote at the meeting or any adjournment thereof. Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders of MannKind Corporation to be Held on May 21, 2020 at 10:00 a.m. U.S. Pacific Time. The proxy statement and annual report to stockholders are available at www.mannkindcorp.com. By Order of the Board of Directors David B. Thomson Executive Vice President, General Counsel and Secretary Westlake Village, California April , 2020 |
|
|
|
Post by otherottawaguy on Apr 1, 2020 7:52:30 GMT -5
Hate to say it but pre-market is not liking the idea of the dilution thus far at 0852h.
Bid: 0.91
Ask: 0.94
Last: 0.93
|
|
